Pre-existing atrial fibrillation and risk of arterial thromboembolism and death following pneumonia: A populationbased cohort study

BMJ Open

Volumn 4, Issue 11, 2014, Pages

  Gamst, Jacob ^a,b,c   Christiansen, Christian Fynbo ^a   Rasmussen, Bodil Steen ^b   Rasmussen, Lars Hvilsted ^b,c   Thomsen, Reimar Wernich ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c Aalborg Atrial Fibrillation Study Group   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTERIAL THROMBOEMBOLISM; ARTICLE; ARTIFICIAL VENTILATION; AWARENESS; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; DEATH; DRUG USE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PNEUMONIA; PRESCRIPTION; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; ATRIAL FIBRILLATION; DENMARK; MIDDLE AGED; RISK; THROMBOEMBOLISM;

AGED; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; COHORT STUDIES; COMORBIDITY; DEATH; DENMARK; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; RISK; RISK FACTORS; THROMBOEMBOLISM;

EID: 84911997451     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006486     Document Type: Article

References (39)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults. JAMA 2001;285:2370-5.
2. Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013;34:2746-51.
3. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52.
4. Friberg L, Hammar N, Pettersson H, et al. Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur Heart J 2007;28:2346-53.
5. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
6. World Health Organization. The global burden of disease: 2004 update. Geneva, 2008.
7. Søgaard M, Nielsen RB, Schønheyder HC, et al. Nationwide trends in pneumonia hospitalization rates and mortality, Denmark 1997-2011. Respir Med 2014;108:1214-22.
8. Fry AM, Shay DK, Holman RC, et al. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA 2005;294:2712-19.
9. Mandal P, Chalmers JD, Choudhury G, et al. Vascular complications are associated with poor outcome in community-acquired pneumonia. QJM 2011;104:489-5.
10. Corrales-Medina VF, Musher DM, Wells GA, et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 2012;125:773-81.
11. Smeeth L, Thomas SL, Hall AJ, et al. Risk of Myocardial Infarction and Stroke after Acute Infection or Vaccination. N Engl J Med 2004;351:2611-18.
12. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011;39(7 Suppl):30-3.
13. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
14. De Groot V, Beckerman H, Lankhorst GJ, et al. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 2003;56:221-9.
15. Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124.
16. Ehrenstein V, Antonsen S, Pedersen L. Existing data sources for clinical epidemiology: Aarhus University Prescription Database. Clin Epidemiol 2010;2:273-9.
17. Hansen ML, Gadsbøll N, Gislason GH, et al. Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers. Europace 2008;10:395-402.
18. Nielsen AG, Nielsen RB, Riis AH, et al. The impact of statin use on pneumonia risk and outcome: a combined population-based case-control and cohort study. Crit Care 2012;16:R122.
19. Andersen JS, Olivarius NDF, Krasnik A. The Danish National Health Service Register. Scand J Public Health 2011;39:34-7.
20. Pedersen CB, Gøtzsche H, Møller JO, et al. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 2006;53:441-9.
21. Andersen PK, Geskus RB, de Witte T, et al. Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol 2012;41:861-70.
22. Thomsen RW, Riis A, Nørgaard M, et al. Rising incidence and persistently high mortality of hospitalized pneumonia: a 10-year population-based study in Denmark. J Intern Med 2006;259:410-17.
23. Rix TA, Riahi S, Overvad K, et al. Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry. Scand Cardiovasc J 2012;46:149-53.
24. Frost L, Vestergaard P. Alcohol and risk of atrial fibrillation or flutter: a cohort study. Arch Intern Med 2004;164:1993-8.
25. Frost L, Andersen LV, Vestergaard P, et al. Trend in mortality after stroke with atrial fibrillation. Am J Med 2007;120:47-53.
26. Johnsen SP, Overvad K, Sørensen HT, et al. Predictive value of stroke and transient ischemic attack discharge diagnoses in The Danish National Registry of Patients. J Clin Epidemiol 2002;55:602-7.
27. Krarup L-H, Boysen G, Janjua H, et al. Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology 2007;28:150-4.
28. Thomsen RW, Johnsen SP, Olesen AV, et al. Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol 2005;60:534-2.
29. Thomsen RW, Nielsen RB, Nørgaard M, et al. Lifestyle profile among statin users. Epidemiology 2013;24:619-20.
30. Thygesen SK, Christiansen CF, Christensen S, et al. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 2011;11:83.
31. Thomsen RW, Riis A, Kornum JB, et al. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29, 900 patients. Arch Intern Med 2008;168:2081-7.
32. Douglas I, Evans S, Smeeth L. Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ 2011;342:d1642.
33. Mortensen EM, Nakashima B, Cornell J, et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis 2012;55:1466-73.
34. Chalmers JD, Singanayagam A, Murray MP, et al. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008;121:1002-1007.e1.
35. Norbury W, Jeschke M, Herndon D. Metabolism modulators in sepsis: propranolol. Crit Care Med 2007;35:s616-620.
36. Ernawati DK, Stafford L, Hughes JD. Amiodarone-induced pulmonary toxicity. Br J Clin Pharmacol 2008;66:82-7.
37. Milbrandt EB, Reade MC, Lee M, et al. Prevalence and significance of coagulation abnormalities in community-acquired pneumonia. Mol Med 2009;15:438-45.
38. Amaral A, Opal SM, Vincent J-L. Coagulation in sepsis. Intensive Care Med 2004;30:1032-40.
39. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67.